Cellectar Biosciences (CLRB) Registration filing summary

Company overview and business model

• Late-stage clinical biopharmaceutical company focused on developing cancer treatments using a proprietary phospholipid ether drug conjugate (PDC) platform designed to target cancer cells and improve efficacy and safety.

• Plans to develop PDCs both independently and through R&D collaborations.

• Principal executive offices located in Florham Park, New Jersey.

Financial performance and metrics

• As of December 31, 2025, consolidated cash balance was approximately $13.2 million, expected to fund operations into Q2 2027.

• Company expects to continue generating operating losses for the foreseeable future and will require additional capital to execute its regulatory strategy.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by selling stockholders; will receive proceeds only from cash exercise of warrants, estimated at $105 million if fully exercised.

• Any proceeds from warrant exercises will be used for working capital and general corporate purposes.